{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:32:52Z","timestamp":1778923972345,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T00:00:00Z","timestamp":1400544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s11060-014-1477-3","type":"journal-article","created":{"date-parts":[[2014,5,19]],"date-time":"2014-05-19T06:55:20Z","timestamp":1400482520000},"page":"91-100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction"],"prefix":"10.1007","volume":"119","author":[{"given":"Xing-Qi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Gang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Su","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,20]]},"reference":[{"key":"1477_CR1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s11060-011-0565-x","volume":"104","author":"R Henriksson","year":"2011","unstructured":"Henriksson R, Asklund T, Poulsen HS (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 104:639\u2013646","journal-title":"J Neurooncol"},{"key":"1477_CR2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jnci\/djt005","volume":"11","author":"U Shah","year":"2013","unstructured":"Shah U, Morrison T (2013) A review of the symptomatic management of malignant gliomas in adults. J Natl Compr Canc Netw 11:424\u2013429","journal-title":"J Natl Compr Canc Netw"},{"key":"1477_CR3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.nurt.2009.04.004","volume":"6","author":"DS Bidros","year":"2009","unstructured":"Bidros DS, Vogelbaum MA (2009) Novel drug delivery strategies in neuro-oncology. Neurotherapeutics 6:539\u2013546","journal-title":"Neurotherapeutics"},{"key":"1477_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2010.04.015","volume":"128","author":"L Arko","year":"2010","unstructured":"Arko L, Katsyv I, Park GE, Luan WP, Park JK (2010) Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther 128:1\u201336","journal-title":"Pharmacol Ther"},{"key":"1477_CR5","first-page":"221","volume":"15","author":"MM Mrugala","year":"2013","unstructured":"Mrugala MM (2013) Advances and challenges in the treatment of glioblastoma: a clinician\u2019s perspective. Discov Med 15:221\u2013230","journal-title":"Discov Med"},{"key":"1477_CR6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-011-0749-4","volume":"107","author":"DR Johnson","year":"2012","unstructured":"Johnson DR, O\u2019Neill BP (2012) Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 107:359\u2013364","journal-title":"J Neurooncol"},{"key":"1477_CR7","first-page":"1","volume":"5","author":"RP Thomas","year":"2013","unstructured":"Thomas RP, Recht L, Nagpal S (2013) Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clin Pharmacol 5:1\u20139","journal-title":"Clin Pharmacol"},{"key":"1477_CR8","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1586\/ern.10.32","volume":"10","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain MC (2010) Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 10:1537\u20131544","journal-title":"Expert Rev Neurother"},{"key":"1477_CR9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/era.12.37","volume":"12","author":"TC Johannessen","year":"2012","unstructured":"Johannessen TC, Bjerkvig R (2012) Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther 12:635\u2013642","journal-title":"Expert Rev Anticancer Ther"},{"key":"1477_CR10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3109\/0284186X.2011.644251","volume":"51","author":"S Kilickap","year":"2012","unstructured":"Kilickap S, Oztoprak I, Yucel B (2012) Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme. Acta Oncol 51:544\u2013546","journal-title":"Acta Oncol"},{"key":"1477_CR11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11060-013-1060-3","volume":"112","author":"CK Park","year":"2013","unstructured":"Park CK, Lee SH, Kim TM, Choi SH, Park SH, Heo DS, Kim IH, Jung HW (2013) The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. J Neurooncol 112:277\u2013283","journal-title":"J Neurooncol"},{"key":"1477_CR12","first-page":"1099","volume":"32","author":"M Santoni","year":"2012","unstructured":"Santoni M, Paccapelo A, Burattini L, Onofri A, Cascinu S (2012) Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma. Anticancer Res 32:1099\u20131101","journal-title":"Anticancer Res"},{"key":"1477_CR13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1874467210801010050","volume":"1","author":"RG Shao","year":"2008","unstructured":"Shao RG (2008) Pharmacology and therapeutic applications of enediyne antitumor antibiotics. Curr Mol Pharmacol 1:50\u201360","journal-title":"Curr Mol Pharmacol"},{"key":"1477_CR14","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.7164\/antibiotics.41.1575","volume":"41","author":"JL Hu","year":"1988","unstructured":"Hu JL, Xue YC, Xie MY, Zhang R, Otani T, Minami Y, Yamada Y, Marunaka T (1988) A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot (Tokyo) 41:1575\u20131579","journal-title":"J Antibiot (Tokyo)"},{"key":"1477_CR15","first-page":"1445","volume":"17","author":"J Chen","year":"2007","unstructured":"Chen J, Ouyang ZG, Zhang SH, Zhen YS (2007) Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Oncol Rep 17:1445\u20131451","journal-title":"Oncol Rep"},{"key":"1477_CR16","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.7164\/antibiotics.42.1294","volume":"42","author":"YS Zhen","year":"1989","unstructured":"Zhen YS, Ming XY, Yu B, Otani T, Saito H, Yamada Y (1989) A new macromolecular antitumor antibiotic, C-1027 III. Antitumor activity. J Antibiot (Tokyo) 42:1294\u20131298","journal-title":"J Antibiot (Tokyo)"},{"key":"1477_CR17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejps.2012.09.002","volume":"47","author":"Q Ru","year":"2012","unstructured":"Ru Q, Shang BY, Miao QF, Li L, Wu SY, Gao RJ, Zhen YS (2012) A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity. Eur J Pharm Sci 47:781\u2013789","journal-title":"Eur J Pharm Sci"},{"key":"1477_CR18","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1021\/bi00185a036","volume":"33","author":"YJ Xu","year":"1994","unstructured":"Xu YJ, Zhen YS, Goldberg IH (1994) C1027 chromophore, a potent new enediyne antitumor antibiotic, induces sequencespecific doublestrand DNA cleavage. Biochemistry 33:5947\u20135954","journal-title":"Biochemistry"},{"key":"1477_CR19","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1126\/science.1072110","volume":"297","author":"W Liu","year":"2002","unstructured":"Liu W, Christenson SD, Standage S, Shen B (2002) Biosynthesis of the enediyne antitumor antibiotic C-1027. Science 297:1170\u20131173","journal-title":"Science"},{"key":"1477_CR20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jsb.2010.08.007","volume":"172","author":"YB Wang","year":"2010","unstructured":"Wang YB, Zhao X, Yu H, Huang XR (2010) Releasing of the chromophore from the drug delivery protein C-1027: a molecular dynamics simulations study. J Struct Biol 172:284\u2013293","journal-title":"J Struct Biol"},{"key":"1477_CR21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/0008-5472.CAN-06-2893","volume":"67","author":"DR Kennedy","year":"2007","unstructured":"Kennedy DR, Gawron LS, Ju J, Liu W, Shen B, Beerman TA (2007) Single chemical modifications of the C-1027 enediyne core, a radiomimetic antitumor drug, affect both drug potency and the role of ataxia-telangiectasia mutated in cellular responses to DNA double-strand breaks. Cancer Res 67:773\u2013781","journal-title":"Cancer Res"},{"key":"1477_CR22","first-page":"597","volume":"17","author":"X Liu","year":"2007","unstructured":"Liu X, Bian C, Ren K, Jin H, Li B, Shao RG (2007) Lidamycin induces marked G2 cell cycle arrest in human colon carcinoma HT-29 cells through activation of p38 MAPK pathway. Oncol Rep 17:597\u2013603","journal-title":"Oncol Rep"},{"key":"1477_CR23","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1158\/0008-5472.CAN-05-0015","volume":"65","author":"MM McHugh","year":"2005","unstructured":"McHugh MM, Gawron LS, Matsui S, Beerman TA (2005) The antitumor enediyne C-1027 alters cell cycle progression and induces chromosomal aberrations and telomere dysfunction. Cancer Res 65:5344\u20135351","journal-title":"Cancer Res"},{"key":"1477_CR24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/187152008783497055","volume":"8","author":"RG Shao","year":"2008","unstructured":"Shao RG, Zhen YS (2008) Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology. Anticancer Agents Med Chem 8:123\u2013131","journal-title":"Anticancer Agents Med Chem"},{"key":"1477_CR25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-010-0492-2","volume":"104","author":"H Chen","year":"2011","unstructured":"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L (2011) PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts. J Neurooncol 104:155\u2013167","journal-title":"J Neurooncol"},{"key":"1477_CR26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11060-011-0680-8","volume":"106","author":"G Xi","year":"2012","unstructured":"Xi G, Mania-Farnell B, Rajaram V, Mayanil CS, Soares MB, Tomita T, Goldman S (2012) Efficacy of interstitial continuous vincristine infusion in a bioluminescent rodent intracranial tumor model. J Neurooncol 106:261\u2013270","journal-title":"J Neurooncol"},{"key":"1477_CR27","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1158\/1078-0432.CCR-04-0308","volume":"10","author":"P Mukherjee","year":"2004","unstructured":"Mukherjee P, Abate LE, Seyfried TN (2004) Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 10:5622\u20135629","journal-title":"Clin Cancer Res"},{"key":"1477_CR28","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/1078-0432.CCR-06-0833","volume":"12","author":"C Bianco","year":"2006","unstructured":"Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, Ricciardi S, Del Tacca M, Raben D, Cionini L, Danesi R (2006) Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 12:7099\u20137107","journal-title":"Clin Cancer Res"},{"key":"1477_CR29","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00280-012-1827-9","volume":"69","author":"JH Gong","year":"2012","unstructured":"Gong JH, Liu XJ, Li Y, Zhen YS (2012) Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice. Cancer Chemother Pharmacol 69:1323\u20131332","journal-title":"Cancer Chemother Pharmacol"},{"key":"1477_CR30","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/j.1349-7006.2009.01315.x","volume":"100","author":"T Matsuzaki","year":"2009","unstructured":"Matsuzaki T, Yashiro M, Kaizaki R (2009) Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 100:2402\u20132410","journal-title":"Cancer Sci"},{"key":"1477_CR31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1215\/15228517-2007-006","volume":"9","author":"S Kesari","year":"2007","unstructured":"Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O\u2019Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY (2007) Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 9:354\u2013363","journal-title":"Neuro Oncol"},{"key":"1477_CR32","first-page":"33","volume":"16","author":"JT Kim","year":"2006","unstructured":"Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, Son MJ, Song HS, Shin HJ, Lee DS, Eoh W, Nam DH (2006) Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 16:33\u201339","journal-title":"Oncol Rep"},{"key":"1477_CR33","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","volume":"77","author":"M Weller","year":"2011","unstructured":"Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R (2011) Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma. Neurology 77:1156\u20131164","journal-title":"Neurology"},{"key":"1477_CR34","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3171\/2011.8.JNS11125","volume":"115","author":"R Grossman","year":"2011","unstructured":"Grossman R, Tyler B, Hwang L, Zadnik P, Lal B, Javaherian K, Brem H (2011) Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin. J Neurosurg 115:1139\u20131146","journal-title":"J Neurosurg"},{"key":"1477_CR35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","volume":"29","author":"A Lai","year":"2011","unstructured":"Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:142\u2013148","journal-title":"J Clin Oncol"},{"key":"1477_CR36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.4161\/cbt.6.6.4193","volume":"6","author":"L Chen","year":"2007","unstructured":"Chen L, Jiang J, Cheng C, Yang A, He Q, Li D et al (2007) P53 dependent and independent apoptosis induced by lidamycin in human colorectal cancer cells. Cancer Biol Ther 6:965\u2013973","journal-title":"Cancer Biol Ther"},{"key":"1477_CR37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12185-009-0340-3","volume":"90","author":"YZ Zhen","year":"2009","unstructured":"Zhen YZ, Lin YJ, Shang BY, Zhen YS (2009) Enediyne lidamycin induces apoptosis in human multiple myeloma cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase. Int J Hematol 90:44\u201351","journal-title":"Int J Hematol"},{"key":"1477_CR38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10495-010-0553-1","volume":"16","author":"M Scabini","year":"2011","unstructured":"Scabini M, Stellari F, Cappella P, Rizzitano S, Texido G, Pesenti E (2011) In vivo imaging of early stage apoptosis by measuring real-time caspase-3\/7 activation. Apoptosis 16:198\u2013207","journal-title":"Apoptosis"},{"key":"1477_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-008-9527-3","volume":"88","author":"M Sandstrom","year":"2008","unstructured":"Sandstrom M, Johansson M, Bergstrom P, Bergenheim AT, Henriksson R (2008) Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. J Neurooncol 88:1\u20139","journal-title":"J Neurooncol"},{"key":"1477_CR40","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1158\/0008-5472.CAN-04-0540","volume":"64","author":"DZ Qian","year":"2004","unstructured":"Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787\/ZK222584. Cancer Res 64:6626\u20136634","journal-title":"Cancer Res"},{"key":"1477_CR41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11060-009-9875-7","volume":"94","author":"RF Barth","year":"2009","unstructured":"Barth RF, Kaur B (2009) Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol 94:299\u2013312","journal-title":"J Neurooncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1477-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-014-1477-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1477-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:17:51Z","timestamp":1559348271000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-014-1477-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,20]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["1477"],"URL":"https:\/\/doi.org\/10.1007\/s11060-014-1477-3","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,20]]}}}